Please assess the completion status of the following clinical trial:

Trial Title: Patient Convenience Study- NIS RELATE

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~Cohort A:~1. A. Written informed consent prior to participation~2. A. Female and male patients \>= 18 years of age with a diagnosis of non-valvular atrial fibrillation.~3. A. At least 3 months of continuous VKA treatment for stroke prevention prior to baseline assessment.~4. A. Patients switched to Pradaxa® according Summary of Product Characteristics and physician's discretion.~OR~Cohort B:~1. B. Written informed consent prior to participation.~2. B. Female and male patients \>= 18 years of age newly diagnosed with non-valvular atrial fibrillation and no previous treatment for stroke prevention (no use of any oral anticoagulant (OAC) within one year prior to enrolment).~3. B. Stroke prevention treatment initiated with Pradaxa® or VKA according to Summary of Product Characteristics and physician's discretion.~Exclusion criteria:~1. Contraindication to the use of Pradaxa® or VKA as described in the Summary of Product Characteristics (SmPC).~2. Patients receiving Pradaxa® or VKA for any other condition than stroke prevention in atrial fibrillation.~3. Current participation in any clinical trial of a drug or device.~4. Current participation in an European registry on the use of oral anticoagulation in AF.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Switch Patients / A (Type: None): Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
- New Patients / B (Type: None): Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).

Based on this trial design, predict the completion outcome and termination type (if applicable).